TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11192954

Group type: EXPERIMENTAL
Intervention: Home-based walking training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 46
Study: 8873687

Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1382159

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg once daily for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3929201

Group type: EXPERIMENTAL
Intervention: 250 mg of penicillin V
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31884836

Group type: EXPERIMENTAL
Intervention: Artemether emulsion (1%)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Fusidic acid emulsion (5g: 0.1g)
Number of subjects: 73
Study: 31868905

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 592

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 592

Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab
Number of subjects: 592
Study: 29740026

Group type: EXPERIMENTAL
Intervention: Higher genetically determined risk of CAD
Number of subjects: 67809

Group type: EXPERIMENTAL
Intervention: Exclusion of the APOE locus
Number of subjects: 67809
Study: 26984449

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 582

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 582
Study: 24912456

Group type: EXPERIMENTAL
Intervention: STEPPS (Systems Training for Emotional Predictability and Problem Solving) added to treatment as usual (TAU) for BD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) for BD
Number of subjects: 0
Study: 22434467

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mosaicplasty
Number of subjects: 100
Study: 20411863

Group type: EXPERIMENTAL
Intervention: Self-evaluation using video recording of Foley catheterization
Number of subjects: 40

Group type: COMPARATOR
Intervention: Written evaluation guidelines only
Number of subjects: 40
Study: 18826866

Group type: EXPERIMENTAL
Intervention: Deferasirox 20 mg/kg coadministered with digoxin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 16
Study: 15701493

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (Milligan-Morgan technique)
Number of subjects: 84
Study: 12776949

Group type: EXPERIMENTAL
Intervention: Normal-dosage Group (3 mg/kg of heparin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dosage Group (1.5 mg/kg of heparin)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 16
Study: 10979947

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/d) for 75 days after BMT
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 8791964

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 16
Study: 1447585

Group type: EXPERIMENTAL
Intervention: Chest Discomfort Diary (experimental group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no diary)
Number of subjects: 31
Study: 3979665

Group type: EXPERIMENTAL
Intervention: Free choice
Number of subjects: 2

Group type: COMPARATOR
Intervention: Forced choice
Number of subjects: 2

Group type: COMPARATOR
Intervention: Delays
Number of subjects: 2
Study: 31722701

Group type: EXPERIMENTAL
Intervention: Foot morphological variables (Clarke's angle, Wejsflog index, hallux valgus angle, foot width) in girls
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Foot morphological variables (Clarke's angle, Wejsflog index, foot width) in boys
Number of subjects: 200
Study: 30541089

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 180
Study: 26564430

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no platelet-rich fibrin)
Number of subjects: 34
Study: 25218337

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus capecitabine 1000mg/m(2) twice daily and cisplatin 80 mg/m(2) on day 1 every 3 weeks
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo plus capecitabine 1000mg/m(2) twice daily and cisplatin 80 mg/m(2) on day 1 every 3 weeks
Number of subjects: 244
Study: 22337582

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20223367

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (maximum allowed dose of 20 mg)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 177
Study: 18274222

Group type: EXPERIMENTAL
Intervention: Low-dose exercise (20 min/day, 5 days/week for 15 weeks)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High-dose exercise (40 min/day, 5 days/week for 15 weeks)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 94
Study: 15604120

Group type: EXPERIMENTAL
Intervention: Full funding for breast prosthesis
Number of subjects: 102
Study: 11384079

Group type: EXPERIMENTAL
Intervention: Fosinopril (FOS) 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 6.25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9232343

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 units/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 30
Study: 7907184

Group type: EXPERIMENTAL
Intervention: Maintaining the same dose of the neuroleptic over an extended trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Significantly increasing the dose of the same neuroleptic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching to a different class of neuroleptic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative symptoms and acute extrapyramidal side effects (EPS)
Number of subjects: 0
Study: 3300139

Group type: EXPERIMENTAL
Intervention: 1% fusidic acid (Fucithalmic), given twice daily
Number of subjects: 164
Study: 2791372

Group type: EXPERIMENTAL
Intervention: Rate-responsive (RR) pacing mode
Number of subjects: 16

Group type: COMPARATOR
Intervention: Constant rate (VVI) pacing mode
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (quality of life assessment)
Number of subjects: 16
Study: 238413

Group type: EXPERIMENTAL
Intervention: 2 mg of lorazepam
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30885824

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: No Erythropoietin (EPO) treatment (Control)
Number of subjects: 69
Study: 28665874

Group type: EXPERIMENTAL
Intervention: Single-injection PVB at T3-T4 level with 25 mL of 0.5% ropivacaine and 4 subcutaneous sham injections
Number of subjects: 70

Group type: COMPARATOR
Intervention: Multiple-injection PVB from T1 to T5 level with 5 mL of 0.5% ropivacaine injected at each level
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Single-injection PVB
Number of subjects: 70

Group type: COMPARATOR
Intervention: Multiple-injection PVB
Number of subjects: 70
Study: 25952354

Group type: EXPERIMENTAL
Intervention: Nominated friends targeting method
Number of subjects: 5773

Group type: COMPARATOR
Intervention: Randomly selected villagers targeting method
Number of subjects: 5773

Group type: COMPARATOR
Intervention: Indegree targeting method
Number of subjects: 5773
Study: 23861303

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX (in patients with CRP >1.0 mg/dl)
Number of subjects: 637

Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 637
Study: 21653575

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 99

Group type: COMPARATOR
Intervention: ADA diet
Number of subjects: 99
Study: 19348963

Group type: EXPERIMENTAL
Intervention: personal digital assistant‐based cholesterol management intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: intervention similar in intensity and frequency of contact focused on hypertension clinical practice guideline
Number of subjects: 61
Study: 16920893

Group type: EXPERIMENTAL
Intervention: Varenicline (0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg for nonsmokers; 0.01, 0.03, 0.1, 0.3, 1.0, 3.0, and 10.0 mg for smokers)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 15113632

Group type: EXPERIMENTAL
Intervention: Breast‐fed and 1‐ml 30% glucose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Breast‐fed and 1‐ml placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasting and 1‐ml 30% glucose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fasting and 1‐ml placebo
Number of subjects: 120
Study: 11641032

Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA) infants
Number of subjects: 318

Group type: COMPARATOR
Intervention: Appropriate for gestational age (AGA) infants
Number of subjects: 318
Study: 9333792

Group type: EXPERIMENTAL
Intervention: Bilevel therapy with a fixed inspiratory to expiratory pressure ratio of 1:0.6
Number of subjects: 52

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bilevel therapy
Number of subjects: 52
Study: 8498624

Group type: EXPERIMENTAL
Intervention: 11-lesson curriculum focused on drug resistance skills
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: 11-lesson curriculum
Number of subjects: 4000
Study: 3328906

Group type: COMPARATOR
Intervention: Auranofin orally
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Allochrysine intramuscularly
Number of subjects: 46
Study: 29948176

Group type: EXPERIMENTAL
Intervention: Trypan blue 0.15% + brilliant blue 0.05% + lutein 2% (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Trypan blue 0.15% + brilliant blue 0.025% + polyethylene glycol 3350 4% (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Indocyanine green 0.05% (Group 3)
Number of subjects: 45
Study: 26944693

Group type: EXPERIMENTAL
Intervention: Web-based educational programme
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Education plus regular sedation quality feedback using process control charts
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Education plus a novel sedation monitoring technology
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All three interventions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 100
Study: 24661040

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (≤ 1000 kcal per day) for 8 weeks
Number of subjects: 262

Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 262
Study: 23717119

Group type: EXPERIMENTAL
Intervention: Red ginseng (4,500 mg daily for 2 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 20401747

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 19
Study: 17918277

Group type: EXPERIMENTAL
Intervention: 99mTc‐interleukin‐2 scintigraphy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nicotinamide therapy (25 mg/kg/day)
Number of subjects: 42
Study: 17259791

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/day
Number of subjects: 46
Study: 14698695

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Conservative AED treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adverse events incidence and participant withdrawal rates
Number of subjects: 37
Study: 11270479

Group type: EXPERIMENTAL
Intervention: Melatonin plus 5-methoxytryptamine (1 mg/day orally in the early afternoon)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Melatonin alone (20 mg/day orally in the evening)
Number of subjects: 30
Study: 9252932

Group type: EXPERIMENTAL
Intervention: Nafarelin (200 micrograms twice daily)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Leuprolide acetate depot (3.75 mg once monthly)
Number of subjects: 192
Study: 8495861

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis during the perioperative period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term thromboprophylaxis
Number of subjects: 0
Study: 3307549

Group type: EXPERIMENTAL
Intervention: Propofol (P)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methohexital (M)
Number of subjects: 30
Study: 31154805

Group type: EXPERIMENTAL
Intervention: Late winter (n = 98)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Late summer (n = 52)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Children aged 24–48 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Children not using formula milk
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Children not adhering to supplementation guidelines
Number of subjects: 150
Study: 27561449

Group type: EXPERIMENTAL
Intervention: Cladribine containing induction
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 125

Group type: COMPARATOR
Intervention: CK+ MK− and CK+ MK+
Number of subjects: 125
Study: 24282477

Group type: EXPERIMENTAL
Intervention: 240 mg caffeine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 40 lx blue light
Number of subjects: 21

Group type: COMPARATOR
Intervention: white light/placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: blue light/placebo
Number of subjects: 21
Study: 21315212

Group type: COMPARATOR
Intervention: Heparin plus GP IIb/IIIa inhibitor
Number of subjects: 10836

Group type: COMPARATOR
Intervention: Bivalirudin plus GP IIb/IIIa inhibitor
Number of subjects: 10836

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 10836
Study: 19394350

Group type: EXPERIMENTAL
Intervention: High viscosity (HV) yogurt
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low viscosity (LV) yogurt
Number of subjects: 46
Study: 17489290

Group type: EXPERIMENTAL
Intervention: Intention associated with a particular stimulus class (pictures or words)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Material-specific interference effect across two experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking manipulation in another experiment
Number of subjects: 0
Study: 12618736

Group type: EXPERIMENTAL
Intervention: DC shock (90 patients)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Drugs (90 patients)
Number of subjects: 180
Study: 10883557

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 7-week group intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-monitoring/waiting-list control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 60
Study: 8840935

Group type: EXPERIMENTAL
Intervention: Incentive subjects (financial incentive to sleep)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control subjects (no incentive)
Number of subjects: 14
Study: 1621749

Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg three times a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 0
Study: 6431211

Group type: EXPERIMENTAL
Intervention: Milacemide 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Milacemide 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Milacemide 1600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium valproate 600 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piracetam 1600 mg
Number of subjects: 12
Study: 31119782

Group type: EXPERIMENTAL
Intervention: Yanhuning injection combined with azithromycin
Number of subjects: 16144

Group type: EXPERIMENTAL
Intervention: Reduning injection combined with azithromycin
Number of subjects: 16144

Group type: COMPARATOR
Intervention: Azithromycin only
Number of subjects: 16144
Study: 30788925

Group type: EXPERIMENTAL
Intervention: Monocycle (Group A: dexamethasone 40 mg once a day, from day 1 to day 4)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Dicycle (Group B: dexamethasone 40 mg once a day, from day 1 to day 4, day 15 to day 18)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tri-cycle (Group C: dexamethasone 40 mg once a day, from day 1 to day 4, day 15 to day 18, day 29 to day 32)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Monocycle (Group A)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Dicycle (Group B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tri-cycle (Group C)
Number of subjects: 93
Study: 26920104

Group type: EXPERIMENTAL
Intervention: 750mg levornidazole every 24h (q24h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 500mg levornidazole every 12h (q12h)
Number of subjects: 24
Study: 25171270

Group type: EXPERIMENTAL
Intervention: Daily protein intake (DPI) above the median (mean DPI of >1 g/kg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Daily protein intake (DPI) below the median (mean DPI of 0.5 g/kg/day)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Lower DPI
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models and time-adjusted analysis
Number of subjects: 159
Study: 23207335

Group type: EXPERIMENTAL
Intervention: Entecavir monotherapy for 2 years
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Entecavir monotherapy for 3 years
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (non‐antiviral treatment)
Number of subjects: 52
Study: 20708900

Group type: EXPERIMENTAL
Intervention: MI-consistent behaviors (MICO)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: MI-inconsistent behaviors (MIIN)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Reflective listening (a type of MICO behavior)
Number of subjects: 149
Study: 17955941

Group type: EXPERIMENTAL
Intervention: CX717 200 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CX717 400 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CX717 1000 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CX717
Number of subjects: 48
Study: 15878536

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 268

Group type: COMPARATOR
Intervention: Unsuitable for stenting
Number of subjects: 268
Study: 11991779

Group type: EXPERIMENTAL
Intervention: Increased morning warm-up (200% of standard volume: 2,011.68 m)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reduced afternoon warm-up (33% of standard warm-up volume)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard morning warm-up (2,011.68 m)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reduced afternoon warm-up (100% of standard warm-up volume)
Number of subjects: 10
Study: 9708959

Group type: EXPERIMENTAL
Intervention: Tolcapone 100 mg 3 times daily
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg 3 times daily
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Tolcapone (both doses)
Number of subjects: 215
Study: 9150038

Group type: COMPARATOR
Intervention: First generation periodontal probe
Number of subjects: 6

Group type: COMPARATOR
Intervention: Third generation periodontal probe
Number of subjects: 6

Group type: COMPARATOR
Intervention: Inter-probe measurements
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intra-probe measurements
Number of subjects: 6
Study: 2328754

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg/kg rectally as premedication
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no midazolam)
Number of subjects: 20
Study: 6804244

Group type: EXPERIMENTAL
Intervention: desmethyldiazepam (20 mg/kg/day) for one week
Number of subjects: 6
Study: 31519550

Group type: EXPERIMENTAL
Intervention: Very-low-phosphate diet (phosphate-to-protein ratio of 8 mg/g)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-phosphate diet (phosphate-to-protein ratio of 10 mg/g)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Very-low-phosphate diet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-phosphate diet
Number of subjects: 35
Study: 29280664

Group type: EXPERIMENTAL
Intervention: Nutritional supplement with stevia and L-carnitine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Glucose solution (SG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: White bread (PB)
Number of subjects: 19
Study: 25719814

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (educational computer programs)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Computer use experience
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 263
Study: 24679851

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the irradiated side of the face after surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-irradiated side (simulated control)
Number of subjects: 10
Study: 22466911

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Number of subjects: 21
Study: 20062928

Group type: EXPERIMENTAL
Intervention: DZ-697b 60 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DZ-697b 120 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DZ-697b 360 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg
Number of subjects: 20